INHIBITION OF AIDS-ASSOCIATED KAPOSIS-SARCOMA CELL-GROWTH BY DAB(389)-INTERLEUKIN-6

Acquired immune deficiency syndrome-associated Kaposi's sarcoma (AIDS- KS)-derived spindle cells produce and use interleukin 6 (IL-6) among s everal other cytokines as a growth factor. In this study we show that AIDS-KS cells express approximately 1100 high-affinity IL-6 receptors (IL-6R) per cell with a dissociation constant (K-d) of 110 pM. Further more, AIDS-KS cells express the IL-6R alpha subunit, detected as a sin gle 5.0-kb messenger ribonucleic acid species, and the high-affinity c onverting, signal-transducing IL-6R beta subunit designated as gp130. Similarly, tumor tissue obtained from patients with KS and AIDS expres ses IL-6R messenger ribonucleic acid. We have exploited the chimeric f usion toxin DAB(389)-IL-6, which exerts cellular toxicity only to the cells expressing IL-6R. This chimeric protein was engineered by fusion of a truncated diphtheria toxin structural gene, in which the region encoding the native receptor-binding domain was removed and replaced w ith the gene encoding IL-6. DAB(389)-IL-6 inhibited protein synthesis in AIDS-KS-derived spindle cells at very low concentrations (IC50 of 3 .4 x 10(-11) M). Similarly, inhibition of cell viability by DAB(389)-I L-6 was observed at equivalent dose levels (IC50 of 5 X 10(-11)). Thes e effects on protein synthesis and cell viability can be abrogated by recombinant human IL-6, indicating receptor specificity. Thus, DAB(389 )-IL-6 is a potential agent for the treatment of AIDS-associated KS.